TheBioTechReview

Industry Radar

Exploring the latest in Industry Radar.

Jeito Capital's $1.2B Bet: Decoding the Late-Stage Biopharma Investment Thesis in a Volatile Market
Industry Radar

Jeito Capital's $1.2B Bet: Decoding the Late-Stage Biopharma Investment Thesis in a Volatile Market

Beyond the Boardroom Battle: The High-Stakes Proxy Fight Signaling a Biotech Investment Paradigm Shift
Industry Radar

Beyond the Boardroom Battle: The High-Stakes Proxy Fight Signaling a Biotech Investment Paradigm Shift

Gilead's $4.4 Billion Bet: Decoding the Oncology & Immunology Acquisition Spree
Industry Radar

Gilead's $4.4 Billion Bet: Decoding the Oncology & Immunology Acquisition Spree

Beyond the $137M: How Sidewinder's ADC Tech Bet Reflects a Shifting Biotech Investment Thesis
Industry Radar

Beyond the $137M: How Sidewinder's ADC Tech Bet Reflects a Shifting Biotech Investment Thesis

The $787M Bet: How Earendil Labs' AI Biologics Deal Signals a New Pharma Investment Era
Industry Radar

The $787M Bet: How Earendil Labs' AI Biologics Deal Signals a New Pharma Investment Era

Roche's SMA Drug Halt: A Strategic Retreat in a Saturated Biotech Market
Industry Radar

Roche's SMA Drug Halt: A Strategic Retreat in a Saturated Biotech Market